Phase I study of the ¹⁷⁷Lu-DOTA⁰-Tyr³-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung

Background Lutathera is a 177 Lutetium-labeled somatostatin analog approved for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). Somatostatin receptors are expressed in small cell lung cancer (SCLC). Nivolumab, an anti-PD-1 antibody, may act synergistically with lutathera to generate antitumor immunity. We conducted a phase I study of lutathera plus nivolumab in patients with advanced NETs of the lung. Methods Patients with...